CD38 and plasma cell myeloma: In conclusion, our study is the first to demonstrate that the R2-ISS holds its value as a simple prognostic algorithm for patients at the time of relapsed and/or refractory multiple myeloma and in the era of novel agents, including anti-CD38 monoclonal antibodies.